Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This drug-drug interaction (DDI) study had been designed to investigate the effect of a
moderate CYP 3A inducer efavirenz on the pharmacokinetics of maleate pyrotinib in Chinese
healthy volunteers.